BIOGRAPHY

Klaas Heinemann

Klaas Heinemann leads ZEG Berlin in providing data of quality and integrity to pharmaceutical companies. Klaas sets the organization’s overall direction for its work in pharmacoepidemiology and drug safety.

Klaas Heinemann is a physician and epidemiologist who has headed ZEG Berlin since 2009 and sits on the Kantar Health Europe management board. The principal investigator for many studies, Klaas provides strategic direction as ZEG-Berlin diversifies beyond women’s health studies to bring its data methodology to other realms of health.

Klaas trained in internal medicine at Charite University Hospital, Berlin before completing postgraduate masters degrees in business and administration (Berlin School of Economics, Berlin), and epidemiology (London School of Hygiene and Tropical Medicine, London). Prior to his appointment as managing director, Klaas was an external consultant for ZEG Berlin. Previously he worked in the US and Germany as a Medical Expert in Global Medical Affairs at Schering AG and later Bayer Pharma, planning and managing clinical research focusing on Phase III clinical studies and post-market phase IV study design.

PUBLICATIONS

2026
Polished but pointless? Assessing the potential of gold and silver-alloy IUDs versus copper-only devices in a large multinational cohort (EURAS- LCS12)  Boehnke Tanja, Lisa Eggebrecht, Rizzo Manuel, Klinghardt Moritz, Klaas Heinemann 2026 Contraception & Reproductive Health Care → DOI
Contraception
2025
Endometriosis and risk of depression among oral contraceptive users: a pooled analysis of cohort studies from 13 countries Pauline De Corte, Milhoranca Igor Andre, Oberg Anna Sara, Kurth Tobias, Mechsner Sylvia, Klaas Heinemann 2025 Human Reproduction. 2025; 1-8. 10.1093/humrep/deae299. → DOI
Endometriosis
Population characteristics of intrauterine device users in real-world clinical practice across Europe – insights from the EURAS-LCS12 study Lisa Eggebrecht, Bauerfeind Anja, Boehnke Tanja, Rizzo Manuel, Hagemann Christine, Jens A. Lange, Viet Mareike, Karl Pauls, von Stockum Sophia, Klinghardt Moritz, Klaas Heinemann 2025 Contraception and Reproductive Medicine. 2025; 10.1186/s40834-025-00353-8. → DOI
Contraception
Real-world use of antispasmodic drugs during IUD insertion – insights from the large observational study EURAS-LCS12 Lisa Eggebrecht, Rizzo Manuel, Klinghardt Moritz, Boehnke Tanja, Clare Barnett, Klaas Heinemann 2025 Contraception & Reproductive Health Care . 2025; 10.1080/13625187.2025.2480086. → DOI
Contraception
Risk of venous thromboembolism associated with chlormadinone acetate- and levonorgestrel-containing combined oral contraceptives – Insights from the retrospective RIVET-RCS study Pauline De Corte, Klinghardt Moritz, Bauerfeind Anja, Boehnke Tanja, Klaas Heinemann 2025 Contraception. 2025; 10.1016/j.contraception.2025.111251. → DOI
Contraception
Use of oral medications prior to IUD insertion – Trends and associations of patient characteristics in a large observational study in Europe (EURAS-LCS12) Klinghardt Moritz, Rizzo Manuel, Boehnke Tanja, Clare Barnett, Klaas Heinemann, Lisa Eggebrecht 2025 Eur J Obstet Gynecol Reprod Biol.. 2025; 10.1016/j.ejogrb.2025.114789. → DOI
Contraception
2024
Venous Thromboembolic Risk of Estradiol Valerate–Dienogest Compared with Ethinyl Estradiol–Levonorgestrel Combined Oral Contraceptives. Bauerfeind Anja, von Stockum Sophia, Boehnke Tanja, Klaas Heinemann 2024 Obstetrics & Gynecology. 2024; 10.1097/AOG.0000000000005509. → DOI
Contraception
Does the shape of the copper intrauterine device play a role in expulsion? Results from the ongoing European Active Surveillance Study on LCS12 Boehnke Tanja, Bauerfeind Anja, Lisa Eggebrecht, Cellier Camille, Jens A. Lange, Klaas Heinemann, Madden Tessa 2024 Contraception. 2024; https://doi.org/10.1016/j.contraception.2024.110444. → DOI
Contraception
Impact of progestin type on the risk of drug interactions between combined oral contraceptives and psychotropic drugs: A pooled analysis of real-world data Boehnke Tanja, Franke Christian, Bauerfeind Anja, Klaas Heinemann, Kolberg-Liedtke Cornelia, Koelkebeck Katja 2024 Contraception. 2024; 10.1016/j.contraception.2024.110786. → DOI
Contraception
Time to Diagnose Endometriosis: Current Status, Challenges and Regional Characteristics – A Systematic Literature Review Pauline De Corte, Klinghardt Moritz, von Stockum Sophia, Klaas Heinemann 2024 BJOG: An International Journal of Obstetrics & Gynaecology. 2024; 1-13. 10.1111/1471-0528.17973. → DOI
Endometriosis
Unravelling the Causal Relationship between Endometriosis and the Risk for Developing Venous Thromboembolism: A Pooled Analysis Pauline De Corte, Milhoranca Igor Andre, Mechsner Sylvia, Oberg Anna Sara, Kurth Tobias, Klaas Heinemann 2024 Thrombosis and Haemostasis. 2024; 10.1055/a-2407-9498. → DOI
Endometriosis
2023
How did regional lockdowns during the COVID-19 pandemic affect recruitment into a large multinational cohort study of intrauterine device users? Boehnke Tanja, Lisa Eggebrecht, Viet Mareike, Klaas Heinemann, Bauerfeind Anja 2023 Contraception. 2023; 10.1016/j.contraception.2023.110003. → DOI
Contraception
2022
Pregnancy and pregnancy outcomes in a prospective cohort study: Final Results from the Nexplanon Observational Risk Assessment Study (NORA) Reed Suzanne, Do Minh Thai, Jens A. Lange, Koro Carol, Klaas Heinemann 2022 Contraception. 2022; 10.1016/j.contraception.2022.109920. → DOI
Contraception
Thromboembolic safety of norethisterone vs levonorgestrel in combined oral contraceptive users: a pooled analysis of 4 large prospective cohort studies Clare Barnett, Bauerfeind Anja, von Stockum Sophia, Klaas Heinemann 2022 AJOG Global Report. 2022; 10.1016/j.xagr.2021.100041. → DOI
Contraception
2021
Long-term treatment of endometriosis with dienogest: Real-world results from the VIPOS study Moehner Sabine, Becker Kerstin, Jens A. Lange, von Stockum Sophia, Serrani Marco, Klaas Heinemann 2021 Journal of Endometriosis and Pelvic Pain Disorders. 2021; 10.1177/2284026521993688. → DOI
Endometriosis

Get in touch

Send a message to the team member.